trending Market Intelligence /marketintelligence/en/news-insights/trending/I0efyZfbCuNuLPlu4JBydQ2 content esgSubNav
In This List

RegeneRx to receive EU patent for neural injury drug

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery


RegeneRx to receive EU patent for neural injury drug

RegeneRx Biopharmaceuticals Inc.'s neural injury drug RGN-352 is set to receive patent protection in Europe.

The European Patent Office notified the company of its intent to grant patent protection through March 26, 2030.